Media ReleasesCellmid Limited

View All Cellmid Limited News

Cellmid Ltd, Annual Financial Report - 30 June 2013

Review of Operations

The Group has grown its Consumer Health Business significantly during the reporting period and, with the acquisition of Advangen Inc., opened up a global opportunity for the commercialisation of its FGF-5 inhibitor hair growth products.

The Midkine Business has reached critical product development objectives in relation to the midkine antibody program and commencing the studies necessary for the 'first in man' phase 1/2a clinical trials of its anti-midkine antibodies in multiple solid tumours.  Significant progress has also been achieved in the Group's diagnostic business with the launch of the first commercial product with midkine as a biomarker, CxBladder by Pacific Edge Limited, and a new option to license agreement with Fujikura Kasei (Japan).

To view Report please download PDF below:

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.